Searchable abstracts of presentations at key conferences in endocrinology

ea0049ep603 | Diabetes therapy | ECE2017

Glycemic control and weight evolution in DM2 patients with canaglifozina

de Linares Lidia Urbon Lopez , Soto Cristina Crespo , Terroba Concepcion , Garrote Sara , Ventosa Marta , Marin Tomas , Cuellar Luis

In the late years ISGLT2 have became an usual choice to treat diabetes. The inhibition of the sodium-glucose co transporters (SLGT2) inhibits also the glucose reabsorption in the proximale tubule and increases the glucose excreted in the urine. Therefore hyperglycemia decreases and so does weight. This is a very convenient side effect since type 2 DM is highly associated with overweight/obesity. We show the results of HbA1c and weight evolution after starting canaglifozina 100...

ea0041ep550 | Diabetes therapy | ECE2016

Effects in weight loss and HbA1c after one year of use of dapaglifozina

de Linares Lidia Urbon Lopez , Soto Maria Cristina Crespo , Terroba Concepcion , Ventosa Marta , Martin Tomas , Calleja Maria del Mar , Cuellar Luis Angel

Changes in HbA1c and weight after 1 year on dapaglifozina added to the previous treatment.SGLT2 inhibitors are becoming a common and useful drug to treat type 2 diabetes.The inhibition of the sodium-glucose co transporters (SLGT2) inhibits also the glucose reabsorption in the proximale tubule and increases the glucose excreted in the urine.Therefore hyperglycemia decreases and so does weight as happens with t...

ea0037ep475 | Diabetes (complications & therapy) | ECE2015

Glycaemic control and weight evolution in type 2 diabetic patients with dapagliflozina in addition to their previous treatment

de Linares Lidia Urbon Lopez , Soto Maria Cristina Crespo , Vina Marta Ventosa , Larumbre Concepcion Terroba , Monclus Claudia Martin , Martin Tomas Martin , Olmedo Luis Cuellar

Introduction: From November 2013 it is available in Spain a new drug to treat type 2 diabetes (DM2): dapagliflozina. The new mechanism of action consists in the inhibition of the sodium–glucose co transporters (SLGT2) inhibiting glucose reabsorption in the proximale tubule and increasing glucose excreted in the urine. Therefore hyperglycaemia decreases and so does weight as a consequence of glycosuria. This is a very convenient side effect since DM2 is highly associated w...

ea0063p76 | Calcium and Bone 1 | ECE2019

Value of ultrasonography guided fine-needle-aspiration in the diagnosis of an intrathyroidal parathyroid adenoma associated with thyroid pathology

Larumbe Maria Concepcion Terroba , Soto Cristina Crespo , Mures Jose Maria Palacio , Garcia Manuel Acuna , Gonzalez Marcelino Mendo , Vina Marta Ventosa , Goyogana Itciar Anacabe , Baranda Mar Calleja , Sanudo Elisa Gil-Carcedo , Olmedo Luis Cuellar

Introduction: Intrathyroidal parathyroid adenomas (IPA) are a rare cause of primary hyperparathyroidism (PHP) and their differential diagnosis includes other parathyroid and thyroid lesions. Although <7% of parathyroid adenomas are intrathyroidal, this location represents almost 20% of ectopic cases and their preoperative identification can pose difficulties, often being an intraoperative finding.Clinical case: A 70-year-old woman diagnosed with brea...

ea0063p224 | Diabetes, Obesity and Metabolism 1 | ECE2019

Prevalence of psychiatric comorbidities in diabetic patients who are candidates for therapy with SGLT2 inhibitors: clinical and metabolic characteristics

Larumbe Maria Concepcion Terroba , Soto Cristina Crespo , Mures Jose Maria Palacio , Sagrado Manuel Gonzalez , Vina Marta Ventosa , Lozano Silvia Pena , Martin Ainara Portela , Baranda Mar Calleja , Vicente Rosa Conde , Olmedo Luis Cuellar

Introduction: Depression, anxiety and eating disorders appear more frequently in patients with type 2 diabetes and are associated with worse metabolic control and higher risk of developing micro and macrovascular complications. The aim of this study was to determine the prevalence of psychiatric comorbidities in diabetic patients, candidates for therapy with SGLT2 inhibitors (SGLT2i) and to evaluate their clinical profile and degree of metabolic control before beginning the tr...

ea0063ep148 | Thyroid | ECE2019

Rhabdomyolysis as clinical presentation of hypothyroidism

Concepcion Maria , Larumbe Terroba , Mures Jose Maria Palacio , Soto Cristina Crespo , Vina Marta Ventosa , Esparza Nerea Eguilaz , Baranda Mar Calleja , Olmedo Luis Cuellar , Roman Daniel De Luis , Carabias Marta Gonzalez

Introduction: Asymptomatic, mild or moderate elevations of creatine phosphokinase are frequently found in hypothyroidism, but rhabdomyolysis is rare, and even more so when it constitutes its clinical presentation.Clinical case: A 26-year-old male who regularly practiced sports, with no family or personal history of interest, went to the emergency room referring to myalgia, generalized cramps, and muscular weakness in the previous two weeks which had not ...